Retrospective results from TDM analysis of antidepressants and antipsychotics were extracted from the LIMS system of the three participating Danish laboratories. These were the Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus (AUH); the Laboratory of the Danish Epilepsy Centre–Filadelfia, Dianalund (EHL); and the Department of Clinical Biochemistry, Rigshospitalet (RH), Copenhagen. Approvals were obtained from the respective hospital boards, prior to downloading the data.
Therapeutic drug monitoring at AUH is carried out by using LC-MS/MS technology and assays that have been developed in-house. The analyses are all accredited according to ISO:15189:2013, and the quality is externally monitored by proficiency testing. Results were extracted for the following drugs covering a period from 1 January 2014 to 31 December 2018: amitriptyline/nortriptyline (metabolite), aripiprazole/dehydroaripiprazole (metabolite), citalopram/escitalopram, clomipramine/desmethylclomipramine (metabolite), clozapine, duloxetine, fluoxetine/norfluoxetine (metabolite), imipramine/desipramine (metabolite), mirtazapine, olanzapine, perphenazine, quetiapine, risperidone/paliperidone (metabolite), sertraline, venlafaxine/o-desmethyl-venlafaxine (metabolite), ziprasidone, and zuclopenthixol.
All the assays performed at EHL have been developed in-house by using LC-MS/MS technology. These include the same drugs as are analysed at AUH and in addition flupentixol, haloperidol, and paroxetine. Although part of the laboratory production, fluoxetine/norfluoxetine, mianserine, and ziprasidone were excluded, owing to a low number of samples (<100). The assays (n = 26) are accredited according to ISO15189:2013, with the exception of aripiprazole/dehydroaripiprazole, and mirtazapine. The quality is externally monitored by proficiency-testing programmes, covering all analytes. For this study, data were collected from the laboratory LIMS system spanning a period from 1 January 2012 to 30 March 2022.
The analyses for therapeutic drugs at RH is performed by HPLC using UV-detection. The following drugs are included in the laboratory repertoire: amitriptyline/nortriptyline, clomipramine/desmethylclomipramine, clozapine, dosulipine/northiaden, and imipramine/desipramine, of which amitriptyline, nortriptyline, clozapine, and imipramine/desipramine are accredited according to ISO 15189:2013. The quality of the assays is monitored by external proficiency-testing schemes. For the calculations, data were collected covering the period from 9 May 2011 to 26 April 2022.
Therapeutic drug monitoring at AUH is carried out by using LC-MS/MS technology and assays that have been developed in-house. The analyses are all accredited according to ISO:15189:2013, and the quality is externally monitored by proficiency testing. Results were extracted for the following drugs covering a period from 1 January 2014 to 31 December 2018: amitriptyline/nortriptyline (metabolite), aripiprazole/dehydroaripiprazole (metabolite), citalopram/escitalopram, clomipramine/desmethylclomipramine (metabolite), clozapine, duloxetine, fluoxetine/norfluoxetine (metabolite), imipramine/desipramine (metabolite), mirtazapine, olanzapine, perphenazine, quetiapine, risperidone/paliperidone (metabolite), sertraline, venlafaxine/o-desmethyl-venlafaxine (metabolite), ziprasidone, and zuclopenthixol.
All the assays performed at EHL have been developed in-house by using LC-MS/MS technology. These include the same drugs as are analysed at AUH and in addition flupentixol, haloperidol, and paroxetine. Although part of the laboratory production, fluoxetine/norfluoxetine, mianserine, and ziprasidone were excluded, owing to a low number of samples (<100). The assays (n = 26) are accredited according to ISO15189:2013, with the exception of aripiprazole/dehydroaripiprazole, and mirtazapine. The quality is externally monitored by proficiency-testing programmes, covering all analytes. For this study, data were collected from the laboratory LIMS system spanning a period from 1 January 2012 to 30 March 2022.
The analyses for therapeutic drugs at RH is performed by HPLC using UV-detection. The following drugs are included in the laboratory repertoire: amitriptyline/nortriptyline, clomipramine/desmethylclomipramine, clozapine, dosulipine/northiaden, and imipramine/desipramine, of which amitriptyline, nortriptyline, clozapine, and imipramine/desipramine are accredited according to ISO 15189:2013. The quality of the assays is monitored by external proficiency-testing schemes. For the calculations, data were collected covering the period from 9 May 2011 to 26 April 2022.
Free full text: Click here
